ArticleDiscover oncology2026
Integration of a glutamine metabolism-based prognostic signature and a synergistic nanotherapeutic strategy targeting metabolic vulnerabilities in prostate cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundProstate cancer (PCa) clinical management is challenged by tumor heterogeneity, driving the need for robust prognostic biomarkers, with altered glutamine metabolism emerging as a promising target. This investigation aimed to construct a metabolism-based prognostic signature for PCa and translate it into a targeted nanotherapeutic strategy.
methodsTranscriptomic data from The Cancer Genome Atlas (TCGA) were analyzed to identify dysregulated glutamine metabolism genes and construct a prognostic model via univariate Cox, LASSO, and multivariate Cox regression with validation in an independent cohort. The model’s characteristics were assessed through tumor microenvironment (TME), tumor mutation burden (TMB), and consensus clustering analyses. The pivotal gene of the model was selected to functionally validate in vitro through proliferation, clonogenicity, migration, and invasion assays. To exploit this vulnerability, a CB/CDDP@lipo nanoplatform was engineered to co-deliver cisplatin and glutaminase inhibitor CB-839, with evaluation in PCa models in vitro and in vivo.
resultsA novel five-gene prognostic signature (ASNS, ATP2B4, GLYATL1, SLC6A20, SLC7A9) was established and stratified PCa patients into high- and low-risk groups based on progression-free interval (PFI). High-risk patients exhibited an immunosuppressive TME, higher TMB and TP53 mutations, and activation of proliferation-related pathways. Functional validation identified ASNS as a key oncogenic driver, enhancing PCa tumor cell proliferation, migration, and invasion. Therapeutically, CB/CDDP@lipo nanoplatform demonstrated potent synergistic cytotoxicity by depleting glutathione (GSH) and amplifying oxidative stress. This dual-action mechanism triggered significant apoptosis and tumor suppression with a favorable safety profile.
conclusionsOur study establishes a glutamine metabolism-based prognostic signature, pinpointing ASNS as a key driver. The resulting CB/CDDP@lipo nanoplatform offers a promising chemo-metabolic strategy for enhanced PCa treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.